Helsinki Health Care, Kettutie 8 M, 00800 Helsinki, Finland.
Int J Antimicrob Agents. 2011 Jan;37(1):22-5. doi: 10.1016/j.ijantimicag.2010.09.013. Epub 2010 Nov 16.
The antimicrobial susceptibility of Helicobacter pylori is an important predictor of the success of eradication therapy. To evaluate recent changes in primary antimicrobial resistance of H. pylori isolated from Finnish patients, the clinical records of H. pylori-positive patients referred for endoscopy to Herttoniemi Hospital (Helsinki, Finland) during 2000-2008 were investigated retrospectively. Stored H. pylori strains from 505 patients without previous eradication therapy were tested for clarithromycin, metronidazole, levofloxacin, tetracycline and amoxicillin susceptibility by Etest. Data on local consumption of antimicrobials were collected and correlations between consumption and resistance were calculated. During the 9-year study period, metronidazole resistance was high (range 29-59%, overall 41%). After an initial increase in clarithromycin resistance (0% in 2000 to 16% in 2003), resistance to clarithromycin decreased to 4% in 2008. No significant correlation was detected between consumption of macrolides and resistance of clarithromycin. Resistance to levofloxacin varied between 0% and 12%. Primary metronidazole resistance in H. pylori is at a high level, however levofloxacin and clarithromycin resistances are still at a reasonable level. Thus, primary clarithromycin resistance in H. pylori in Finland has not become such a problem as in many other countries. Primary resistance to the antimicrobials studied varied considerably from year to year.
幽门螺杆菌的抗菌药物敏感性是根除治疗成功的重要预测因素。为了评估芬兰患者分离的幽门螺杆菌主要抗菌药物原发性耐药性的近期变化,回顾性研究了 2000-2008 年期间因内镜检查而转至芬兰赫尔辛基 Herttoniemi 医院的幽门螺杆菌阳性患者的临床记录。对 505 例未经先前根除治疗的患者的储存幽门螺杆菌菌株进行了克拉霉素、甲硝唑、左氧氟沙星、四环素和阿莫西林敏感性的 Etest 检测。收集了关于当地抗菌药物使用的数据,并计算了消耗量与耐药性之间的相关性。在 9 年的研究期间,甲硝唑耐药率较高(范围 29-59%,总体 41%)。克拉霉素耐药性最初有所增加(2000 年为 0%,2003 年为 16%),随后在 2008 年降至 4%。未发现克拉霉素耐药性与大环内酯类药物消耗量之间存在显著相关性。左氧氟沙星耐药率在 0%至 12%之间变化。幽门螺杆菌的原发性甲硝唑耐药率较高,但左氧氟沙星和克拉霉素的耐药率仍处于合理水平。因此,芬兰幽门螺杆菌的原发性克拉霉素耐药性尚未成为许多其他国家那样的问题。研究中抗菌药物的原发性耐药性每年变化很大。